Sources
https://www.gilead.com/news-and-press/press-room/press-releases/2024/3/gilead-sciences-announces-completion-of-acquisition-of-cymabay
https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217899s000lbl.pdf
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-axatilimab-csfr-chronic-graft-versus-host-disease
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-neoadjuvantadjuvant-durvalumab-resectable-non-small-cell-lung-cancer?utm_medium=email&utm_source=govdelivery
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-lazertinib-amivantamab-vmjw-non-small-lung-cancer?utm_medium=email&utm_source=govdelivery
https://www.citeline.com/-/media/citeline/resources/pdf/white-paper_why-are-clinical-development-success-rates-falling.pdf
https://www.bio.org/clinical-development-success-rates-and-contributing-factors-2011-2020
https://go.bio.org/rs/490-EHZ-999/images/ClinicalDevelopmentSuccessRates2011_2020.pdf
https://www.norstella.com/why-clinical-development-success-rates-falling/
https://public4.pagefreezer.com/browse/FDA/10-06-2024T13:24/https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2017
https://ir.actiniumpharma.com/press-releases/detail/18/actinium-pharmaceuticals-announces-plans-for-iomab-b
https://ir.actiniumpharma.com/press-releases/detail/92/actinium-initiates-cgmp-manufacturing-of-iomab-b-for-phase
https://ir.actiniumpharma.com/press-releases/detail/486/actinium-provides-regulatory-update-on-planned-bla-filing
https://www.fda.gov/science-research/science-and-research-special-topics/real-world-evidence
